AMENDMENT NO. 1 TO THE HERCEPTIN LICENSE AGREEMENTHerceptin License Agreement • March 8th, 2004 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances)
This Amendment No. 1 To The Herceptin License Agreement (“Amendment”) is entered into as of December 18, 2003 by and between Genentech, Inc. (“GNE”), a Delaware corporation having offices at 1 DNA Way, South San Francisco, California 94080 and Protein Design Labs, Inc. (“PDL”), a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (collectively, the “Parties”) and amends that certain PDL License Agreement dated November 3, 1998 (the “Herceptin License Agreement”). Except as expressly provided herein, capitalized terms shall have the meanings set forth in the Herceptin License Agreement.
